Management of hepatitis C in children and adolescents during COVID-19 pandemic

Table 1 Direct-acting antivirals approved for adolescents aged 12 to 17 years in Europe (May 2020)[20,22-24]

Direct-acting antivirals regimen (doses per d)	Hepatitis C virus genotype	Patients	Duration of treatment in wk
Sofosbuvir/ledipasvir (400/90 mg)	1	Treatment-naïve with or without cirrhosis or treatment-experienced without cirrhosis	12
		Treatment-experienced with cirrhosis	24
	4, 5, 6	Treatment-naïve or treatment-experienced, with or without cirrhosis	12
Sofosbuvir + ribavirin (400 mg + 15 mg/kg)	2	Treatment-naïve or treatment-experienced, with or without cirrhosis	12
	3		24
Glecaprevir/pibrentasvir (300/120 mg)	All genotypes	Without cirrhosis	8
	All genotypes	With cirrhosis	12
	3	Treatment experienced	16